New treatment against SARS-CoV-2 now is a must. Nowadays, the world encounters a huge
health crisis by the COVID-19 viral infection. Nucleotide inhibitors gave a lot of promising …

The rapid spread of the virus, the surge in the number of deaths, and the unavailability of
specific SARS-CoV-2 drugs thus far necessitate the identification of drugs with anti-COVID …

Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …

Structural aspects of molnupiravir complexed with the RNA of the SARS-CoV-2 virus have
been recently resolved inside the RNA-dependent RNA polymerase (RdRp), demonstrating …

The COVID-19 pandemic continues to be a public health threat with emerging variants of
SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the …

Abstract Treatment of SARS-CoV-2 targeting its RNA dependent RNA polymerase (RdRp) is
of current interest. Remdesivir has been approved for the treatment of COVID-19 around the …

Recent efforts to repurpose drugs to combat COVID-19 have identified Remdesivir as a
candidate. It acts on the RNA-dependent, RNA polymerase (RdRp) of the SARS-CoV-2 …

The COVID-19 pandemic has caused millions of fatalities since 2019. Despite the
availability of vaccines for this disease, new strains are causing rapid ailment and are a …

Molecular dynamics (MD) simulations are powerful theoretical methods that can reveal
biomolecular properties, such as structure, fluctuations, and ligand binding, at the level of …

Favipiravir was initially developed as an antiviral drug against influenza and is currently
used in clinical trials against severe acute respiratory syndrome coronavirus-2 (SARS-CoV …